Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management
Jan Stenvang is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research.Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, strengthens its Executive Management with the inclusion of Jan Stenvang, who is appointed Chief Scientific Officer (CSO) reporting directly to CEO Francois Martelet. A co-founder of Scandion, Jan Stenvang led the initial research and discoveries upon which Scandion is based. He has headed the company’s research and early